Liraglutide is indicated as an adjunct to a reduced-energy diet and increased physical activity for weight loss management in adults with a BMI 30 kg/m 2 or BMI of 27 kg/m 2 and at least one weight-related comorbidity, including type 2 diabetes mellitus, hypertension, dyslipidaemia, or obstructive sleep apnoea
Additionally, in the trial examining alcohol use disorder, a significant reduction in alcohol consumption was observed only in a specific subgroup of patients with obesity, suggesting that patient characteristics, such as BMI, might influence treatment outcomes
Approved for long-term use (more than 12 weeks)
Awareness is powerful, but a core challenge in lifestyle change is the human tendency to prioritize immediate comfort over future health what behavioral economists call present bias
Strategies like eating adequate protein, getting enough fiber, and staying well hydrated can help support appetite control and satiety
A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease
